350 related articles for article (PubMed ID: 25997442)
21. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
[TBL] [Abstract][Full Text] [Related]
22. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR
Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262
[TBL] [Abstract][Full Text] [Related]
23. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.
Chen F; Jin L; Nie Z
J Pharm Pharm Sci; 2017; 20(0):285-294. PubMed ID: 28810946
[TBL] [Abstract][Full Text] [Related]
25. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.
Kassubek J; Chaudhuri KR; Zesiewicz T; Surmann E; Boroojerdi B; Moran K; Ghys L; Trenkwalder C
BMC Neurol; 2014 Mar; 14():42. PubMed ID: 24602411
[TBL] [Abstract][Full Text] [Related]
26. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
27. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
28. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study.
Pierantozzi M; Placidi F; Liguori C; Albanese M; Imbriani P; Marciani MG; Mercuri NB; Stanzione P; Stefani A
Sleep Med; 2016 May; 21():140-4. PubMed ID: 27448485
[TBL] [Abstract][Full Text] [Related]
29. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
Nomoto M; Iwaki H; Kondo H; Sakurai M
J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
[TBL] [Abstract][Full Text] [Related]
31. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
Jankovic J; Watts RL; Martin W; Boroojerdi B
Arch Neurol; 2007 May; 64(5):676-82. PubMed ID: 17502466
[TBL] [Abstract][Full Text] [Related]
32. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
[TBL] [Abstract][Full Text] [Related]
33. Rotigotine: in Parkinson's disease.
Reynolds NA; Wellington K; Easthope SE
CNS Drugs; 2005; 19(11):973-81. PubMed ID: 16268667
[TBL] [Abstract][Full Text] [Related]
34. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
[TBL] [Abstract][Full Text] [Related]
35. Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER Study.
Swick TJ; Friedman JH; Chaudhuri KR; Surmann E; Boroojerdi B; Moran K; Ghys L; Trenkwalder C
Eur Neurol; 2014; 71(3-4):140-7. PubMed ID: 24457253
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
[TBL] [Abstract][Full Text] [Related]
38. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
39. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P
Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560
[TBL] [Abstract][Full Text] [Related]
40. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Rascol O; Perez-Lloret S
Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
